1. [CASE 1 -- QUESTION 1] The ophthalmologist performs pharmacological pupillary testing. Cocaine 10% eye drops are instilled in both eyes. Forty-five minutes later, the left (normal) pupil has dilated from 5 mm to 8 mm. The right (Horner) pupil has not dilated and remains at 2 mm. Which of the following most accurately interprets this cocaine test result, and what additional pharmacological test would be required to localize the lesion within the three-neuron sympathetic chain?

• A) The cocaine test confirms the sympathetic pathway is interrupted at some level in the right eye -- the left pupil dilated because cocaine blocked NE reuptake at intact postganglionic terminals, accumulating NE at the alpha-1 receptor and producing mydriasis; the right pupil failed to dilate because cocaine cannot function without intact postganglionic terminals releasing NE tonically; this result is consistent with any level of disruption (first, second, or third order); hydroxyamphetamine 1% instilled 48 hours later would distinguish the level: dilation of the right pupil confirms a first- or second-order lesion with intact third-order neuron and NE stores; failure to dilate confirms a third-order postganglionic lesion.
• B) The cocaine test confirms a specific third-order postganglionic lesion -- cocaine can only fail to dilate the pupil when the third-order neuron itself is disrupted, because cocaine's mechanism of NE reuptake blockade requires the third-order terminal to be the site of drug action; first- and second-order lesions do not affect cocaine's efficacy; no further pharmacological localization is needed since the cocaine result has already established the third-order diagnosis.
• C) The cocaine test result confirms a sympathetic pathway lesion somewhere in the right eye's three-neuron chain, but the cocaine test alone cannot localize the lesion to a specific neuron; in the context of the apical mass with rib erosion, the lesion is almost certainly at the second-order neuron traveling over the pulmonary apex; to pharmacologically confirm whether the third-order neuron is intact, hydroxyamphetamine 1% should be instilled 48 hours after the cocaine test -- dilation with hydroxyamphetamine would confirm an intact third-order neuron (consistent with a second-order lesion from the Pancoast mass), while failure to dilate would implicate third-order neuron disruption.
• D) The cocaine test is not interpretable in this patient because the right pupil's failure to dilate could reflect either a sympathetic lesion or primary iris sphincter scarring from the apical mass -- topical atropine 1% should be administered first to verify that the iris dilator and sphincter muscles are pharmacologically responsive before interpreting cocaine's failure as evidence of sympathetic disruption.
• E) The cocaine test confirms a first-order (central) Horner syndrome lesion -- cocaine's failure to dilate the right pupil despite successful dilation of the left indicates that the central descending sympathetic pathway from the hypothalamus is disrupted, since first-order lesions uniquely prevent cocaine from accessing the NE stored at the superior cervical ganglion; imaging of the hypothalamus and brainstem should be urgently obtained to identify the central lesion responsible for the failed cocaine test.

2. [CASE 1 -- QUESTION 2] The anesthesiology team plans a right stellate ganglion block for intraoperative and postoperative pain management during Pancoast resection. Which of the following most accurately describes the expected autonomic consequences of a successful right stellate ganglion block, and explains why the anesthesiologist cannot rely on the standard confirmatory endpoint of ipsilateral Horner syndrome to verify adequate block in this patient?

• A) A successful right stellate ganglion block produces ipsilateral Horner syndrome (ptosis, miosis, anhidrosis) as the confirmatory sign of adequate blockade -- and additionally produces ipsilateral upper extremity vasodilation and increased skin temperature from loss of alpha-1-mediated vasoconstrictor tone; in this patient, the stellate block cannot be confirmed by ipsilateral Horner appearance because the patient already has a pre-existing right Horner syndrome from the second-order neuron disruption -- the right pupil is already maximally miotic and the right eyelid already has ptosis; the anesthesiologist must rely on ipsilateral upper extremity temperature change (skin temperature increase greater than 1-1.5 degrees Celsius) and abolition of ipsilateral hand sweating as alternative adequacy endpoints.
• B) A successful right stellate ganglion block produces contralateral Horner syndrome because the stellate ganglion's sympathetic fibers cross the midline at the level of the cervicothoracic junction before ascending to the superior cervical ganglion -- blocking the right stellate ganglion therefore removes sympathetic tone from the left eye; this contralateral effect distinguishes stellate ganglion block from superior cervical ganglion block, which produces ipsilateral effects only.
• C) A successful right stellate ganglion block produces bilateral upper extremity vasodilation because the stellate ganglion provides the principal vasomotor input to both upper extremities through the brachial plexus sympathetic gray rami -- blocking it removes sympathetic vasoconstrictor tone from both arms simultaneously; the expected bilateral warming would be the confirmatory sign of adequate block, and the patient's pre-existing Horner syndrome would not affect this assessment.
• D) A successful right stellate ganglion block produces ipsilateral phrenic nerve palsy as its primary autonomic consequence -- the stellate ganglion provides tonic sympathetic activation of the ipsilateral hemidiaphragm through the phrenic nerve's sympathetic supply, and blocking it produces right hemidiaphragm paresis with reduced tidal volume on the right; in a patient with a Pancoast tumor already potentially compromising right lung function, this phrenic effect is the most important clinical consideration.
• E) A stellate ganglion block is pharmacologically contraindicated in this patient because the pre-existing second-order sympathetic lesion from the Pancoast tumor has already produced denervation supersensitivity of alpha-1 receptors throughout the right upper extremity vasculature -- injecting local anesthetic near the stellate ganglion in the presence of denervation supersensitivity would produce paradoxical right upper extremity vasoconstriction.

3. [CASE 1 -- QUESTION 3] Following neoadjuvant therapy and Pancoast resection, the patient develops postoperative episodes of severe hypertension (BP up to 210/130 mmHg), tachycardia (HR up to 148 bpm), and diaphoresis. The differential diagnosis includes an occult catecholamine-secreting tumor versus sympathetic nervous system disruption-related dysautonomia from the extensive surgical dissection in the cervicothoracic sympathetic chain. The clinical team must decide between initiating empirical alpha-blockade versus ordering urine catecholamine measurement before treating. Which pharmacological argument most rigorously supports measuring catecholamines before initiating empirical alpha-blockade?

• A) Alpha-blockers are absolutely contraindicated after thoracic surgery because they produce peripheral vasodilation that reduces venous return to a heart that is already volume-depleted from the extensive surgical dissection and postoperative fluid shifts -- the risk of cardiovascular collapse from empirical alpha-blockade in the post-Pancoast resection period outweighs any benefit from treating presumed catecholamine excess without confirmation.
• B) Empirical alpha-blockade without catecholamine measurement risks treating surgically-induced autonomic dysreflexia or baroreceptor reflex dysregulation with the wrong mechanism-targeted drug -- surgical disruption of the cervicothoracic sympathetic chain produces complex patterns of denervation and reflex dysregulation including episodic hypertension from loss of baroreceptor afferent input through the NTS circuit; treating this mechanism with alpha-blockade alone may produce paradoxical hypotension in an autonomically unstable post-surgical patient while failing to address the underlying neurogenic mechanism; measuring 24-hour urine catecholamines (metanephrines and normetanephrines) or plasma metanephrines distinguishes catecholamine-secreting tumor from baroreceptor-disruption dysautonomia -- different mechanisms requiring different pharmacological strategies; short-acting titratable agents (IV nicardipine or IV labetalol) can bridge the patient in the interim.
• C) Alpha-blockade must never be initiated before beta-blockade in any hypertensive emergency regardless of mechanism -- the pharmacological principle of beta first, alpha second applies universally to all catecholamine-mediated hypertensive states; initiating alpha-blockade before beta-blockade risks reflex tachycardia from vasodilation that exceeds the cardiac reserve of a 62-year-old post-thoracotomy patient.
• D) Urine catecholamine measurement takes 72 hours to result and the patient requires immediate treatment regardless of mechanism -- the question of whether to measure catecholamines before treating is therefore a false dilemma; the pragmatic approach is to initiate empirical clonidine (centrally acting alpha-2 agonist) because clonidine is pharmacologically appropriate regardless of whether the hypertension is catecholamine-mediated or baroreceptor-reflex-mediated, covering both mechanisms simultaneously.
• E) Empirical phenoxybenzamine (irreversible alpha-blocker) should be initiated immediately without catecholamine measurement because irreversible alpha-1 blockade provides superior protection against catecholamine-surge hypertension compared to competitive reversible alpha-blockers; the irreversible nature of phenoxybenzamine means that even if catecholamine levels are normal and the hypertension is from a different mechanism, the blockade can be reversed by administering exogenous norepinephrine at sufficiently high concentrations to overcome the irreversible binding.

4. [CASE 1 -- QUESTION 4] The patient's urine catecholamines return normal. He is diagnosed with post-surgical autonomic dysreflexia and started on clonidine 0.1 mg twice daily. Three weeks later, discharge instructions inadvertently instruct him to stop clonidine immediately rather than taper. He stops abruptly. Thirty-six hours later he presents to the emergency department with BP 218/136 mmHg, heart rate 108 bpm, agitation, and sweating. Which of the following most accurately explains the receptor-level mechanism of clonidine withdrawal hypertension and identifies the correct treatment?

• A) Abrupt clonidine discontinuation produces rebound hypertension because clonidine irreversibly inhibits central alpha-2 receptors -- permanent alpha-2 blockade from chronic clonidine use cannot be reversed without several weeks of receptor resynthesis; the resulting lack of alpha-2 autoreceptor function eliminates presynaptic NE release inhibition at peripheral sympathetic terminals, producing catecholamine storm; treatment is phenoxybenzamine IV to block the excess NE while new alpha-2 receptors are synthesized.
• B) Abrupt clonidine discontinuation produces rebound hypertension through receptor upregulation -- chronic alpha-2 agonism by clonidine downregulates alpha-2 receptor density and sensitivity throughout the central and peripheral nervous system; abrupt drug removal exposes the downregulated alpha-2 receptors to endogenous NE, producing paradoxical hypertension because the NE cannot activate the downregulated receptors to provide negative feedback; treatment is yohimbine (alpha-2 antagonist) to further block the impaired alpha-2 receptors and prevent NE from attempting (ineffectively) to activate them.
• C) Abrupt clonidine discontinuation produces a sympathetic rebound syndrome: chronic central alpha-2 agonism suppresses sympathetic tone globally, leading to compensatory upregulation of peripheral alpha-1 receptors and increased presynaptic NE synthesis; when clonidine is abruptly withdrawn, the suddenly unoppressed central sympathetic drive activates upregulated peripheral alpha-1 receptors with a larger-than-normal NE surge -- producing rebound hypertension that can exceed pre-treatment levels; treatment requires clonidine reinstatement (to restore central alpha-2 agonism and suppress the sympathetic rebound) or labetalol IV (combined alpha-1 and beta-blockade to address the peripheral catecholamine surge) -- beta-blockade alone risks worsening hypertension by blocking beta-2-mediated vasodilation while leaving alpha-1 vasoconstriction unopposed.
• D) Abrupt clonidine discontinuation produces hypertension through muscarinic M2 receptor upregulation -- chronic alpha-2 agonism cross-regulates cardiac M2 receptors, and withdrawal produces M2 receptor supersensitivity at the SA node, generating paradoxical tachycardia from excess vagal tone that triggers baroreceptor-mediated sympathetic reflex activation and secondary hypertension; treatment is low-dose atropine to block the M2 supersensitivity at the SA node.
• E) Abrupt clonidine discontinuation does not produce rebound hypertension in clinical practice -- this is a theoretical pharmacological concern that has not been validated in clinical trials; the hypertension and tachycardia in this patient represent a separate acute event (possibly myocardial infarction or stroke) unrelated to the clonidine discontinuation; the correct management is emergent cardiac catheterization.

5. [CASE 2 -- QUESTION 1] The combination of generalized anhidrosis with entirely preserved cardiovascular autonomic reflexes, normal pupillary responses, and normal lacrimal and salivary function places this patient's lesion at a very specific anatomical and pharmacological locus within the ANS. Which of the following most accurately identifies the anatomical and pharmacological basis for this isolated anhidrosis, drawing on the unique neurotransmitter pharmacology of eccrine sweat gland innervation?

• A) Generalized anhidrosis with preserved cardiovascular, pupillomotor, lacrimal, and salivary autonomic function is explained by a selective lesion of the parasympathetic sacral outflow (S2-S4) -- the pelvic splanchnic nerves carry both the sacral parasympathetic motor fibers to the pelvic viscera and the secretomotor fibers to the eccrine sweat glands of the lower extremities; the upper extremity anhidrosis reflects ascending spread of the S2-S4 lesion through the spinal cord dorsal columns to involve the thoracic preganglionic sudomotor neurons.
• B) Generalized anhidrosis with preserved cardiovascular and other autonomic functions is explained by selective involvement of the sympathetic cholinergic postganglionic pathway to eccrine sweat glands -- unlike all other sympathetic effector targets (heart, blood vessels, iris dilator pupillae, juxtaglomerular apparatus, adipose tissue) which receive noradrenergic sympathetic postganglionic innervation, eccrine sweat glands receive postganglionic sympathetic innervation that releases acetylcholine rather than norepinephrine; ACh activates M3 muscarinic receptors on the eccrine secretory coil to produce sweat; a selective disorder of this sympathetic cholinergic pathway produces generalized anhidrosis while leaving all noradrenergic sympathetic functions (cardiovascular control, pupillary dilation, vasoconstriction) and all parasympathetic functions (lacrimal, salivary, pupillary light reflex, cardiac vagal tone) entirely intact.
• C) Generalized anhidrosis with preserved other autonomic functions reflects a selective failure of the parasympathetic cranial outflow to sweat glands -- all eccrine sweat glands receive parasympathetic innervation through branches of the facial nerve (CN VII) to the pterygopalatine ganglion and thence through the auriculotemporal nerve to the skin surface; a selective CN VII lesion that spares the lacrimal and salivary branches but affects only the cutaneous sudomotor branches produces the observed clinical picture.
• D) Generalized anhidrosis with preserved other autonomic functions reflects deficiency of vasoactive intestinal peptide (VIP) at eccrine sweat gland terminals -- VIP is the principal cotransmitter at eccrine sweat gland sympathetic terminals and is responsible for approximately 90% of sweating; acetylcholine is a minor cotransmitter responsible for only the remaining 10% of sweat production; a selective VIP deficiency from autoimmune destruction of VIP-containing neurons produces isolated anhidrosis while sparing the minor cholinergic sudomotor pathway and all other autonomic functions.
• E) Generalized anhidrosis with preserved cardiovascular autonomic function is explained by selective downregulation of beta-2 adrenergic receptors at the eccrine sweat gland secretory coil -- eccrine sweating in humans is primarily driven by beta-2 adrenergic receptor activation by circulating epinephrine from the adrenal medulla, not by direct neural input; selective beta-2 receptor downregulation from chronic high-intensity exercise-induced catecholamine exposure explains the pattern of isolated anhidrosis in an infantry soldier.

6. [CASE 2 -- QUESTION 2] QSART testing reveals absent sweat gland response to acetylcholine iontophoresis at all four limb sites. Skin biopsy shows normal intraepidermal nerve fiber density. Genetic testing returns a heterozygous loss-of-function variant in TRPV4. Which of the following most accurately explains the pharmacological principle underlying QSART testing, what the combination of absent QSART with normal skin biopsy indicates about the anatomical level of the deficit, and why pyridostigmine (an AChE inhibitor) would be unlikely to correct this patient's anhidrosis?

• A) QSART delivers acetylcholine iontophoretically to the skin surface, where it is absorbed into the dermis and activates nicotinic receptors at sympathetic nerve terminals, triggering an axon reflex that propagates antidromically along the sympathetic cholinergic axon and then orthodromically along collateral branches to adjacent terminals, where ACh release activates M3 receptors on the eccrine secretory coil producing sweat; absent QSART with normal intraepidermal nerve fiber density indicates the anatomical deficit is at or distal to the neuroeffector junction -- specifically at the sweat gland itself; pyridostigmine would increase ACh concentration at M3 receptors by inhibiting its enzymatic breakdown, but if the deficit is within the sweat gland's downstream signaling cascade (e.g., TRPV4-dependent calcium entry required for aquaporin-mediated water secretion), increasing ACh at M3 cannot overcome a post-receptor transduction failure.
• B) QSART cannot be performed without intact postganglionic sympathetic nerve fibers because the axon reflex component requires the fiber to conduct impulses both antidromically and orthodromically -- absent QSART therefore always indicates small fiber axonal neuropathy; normal skin biopsy (normal nerve fiber density) is inconsistent with absent QSART and indicates that one of the two tests was performed incorrectly; in cases of discordant QSART and biopsy results, QSART should be repeated with higher iontophoresis current before concluding that a true deficit exists.
• C) QSART delivers acetylcholine iontophoretically to activate postganglionic sympathetic terminals, triggering the axon reflex; absent QSART with normal intraepidermal nerve fiber density on biopsy indicates that the nerve fibers are anatomically present but functionally impaired -- either at the neurotransmitter release step, at the M3 receptor, or downstream in the secretory apparatus; the TRPV4 variant supports a post-receptor calcium channel defect since TRPV4 is a calcium-permeable ion channel expressed in eccrine gland secretory cells that contributes to calcium-dependent aquaporin-mediated water secretion; pyridostigmine inhibiting AChE would increase synaptic ACh and augment M3 receptor activation, but cannot restore the downstream TRPV4-dependent calcium entry step -- the deficit is post-receptor, not pre-receptor, making AChE inhibition an ineffective therapeutic strategy for this specific molecular lesion.
• D) QSART detects small fiber autonomic neuropathy by measuring the antidromic vasodilatory response of arterioles to acetylcholine iontophoresis -- absent QSART indicates failure of arteriolar vasodilation rather than sweat gland failure; normal skin biopsy confirming nerve fiber density means the arterioles are denervated rather than the sweat glands; pyridostigmine would be expected to restore arteriolar dilation by increasing ACh at endothelial muscarinic receptors but would not address the denervation-related defect.
• E) QSART testing and skin biopsy both measure the same biological variable (postganglionic sympathetic nerve fiber density at the dermal level) using different methods -- discordant results between QSART and biopsy are therefore always due to technical error in one of the two assays; the TRPV4 variant is irrelevant to the interpretation because TRPV4 is a sensory, not autonomic, ion channel and its loss of function produces sensory neuropathy rather than autonomic dysfunction.

7. [CASE 2 -- QUESTION 3] The medical board must determine whether this soldier is fit for continued active duty in field environments. The examining physician reviews the physiology of thermoregulatory sweating to advise the board. Which of the following most accurately characterizes the role of the sympathetic cholinergic pathway in thermoregulation and explains why complete anhidrosis represents a potentially life-threatening impairment in the specific operational environment of field military service?

• A) Thermoregulatory sweating accounts for less than 10% of total heat dissipation at rest and during moderate exercise -- the dominant heat dissipation mechanisms are radiation (approximately 60%) and convection (approximately 30%); anhidrosis therefore produces only modest thermoregulatory impairment and the risk of heat stroke in a physically fit young soldier is primarily from inadequate hydration rather than sweating deficit; the board should consider duty restriction only in environments above 40 degrees Celsius.
• B) Thermoregulatory sweating is the dominant mechanism of heat dissipation during exercise and in hot environments -- the hypothalamic thermoregulatory center responds to rising core body temperature by increasing sympathetic cholinergic outflow to eccrine sweat glands throughout the body surface; evaporative cooling from sweat production can dissipate up to 600-800 Watts of heat during maximal exercise; without sweating, heat dissipation depends exclusively on radiation and convection -- mechanisms that become inadequate when ambient temperature approaches or exceeds skin temperature; in a soldier performing sustained heavy physical work in hot, humid field conditions, complete anhidrosis produces progressive hyperthermia that rapidly reaches the threshold for heat stroke (core temperature above 40 degrees Celsius), with direct thermal injury to the CNS, rhabdomyolysis, acute kidney injury, DIC, and multi-organ failure -- representing a potentially fatal impairment incompatible with unrestricted field service.
• C) Thermoregulatory sweating is regulated primarily by the parasympathetic system through the vagus nerve -- core temperature elevation is detected by hypothalamic thermoreceptors that increase vagal tone, which then activates eccrine sweat glands through cardiac slowing (reducing heat generation from cardiac work) and peripheral vasodilation (increasing heat loss from skin blood flow); anhidrosis from sympathetic cholinergic pathway failure preserves the vagal thermoregulatory response, and a fit young soldier with intact vagal tone would be able to thermoregulate adequately through the cardiovascular mechanism alone without sweating.
• D) Thermoregulatory sweating is mediated by a combination of beta-2 adrenergic receptors (responsible for 70% of heat-induced sweating) and M3 muscarinic receptors (responsible for 30%) at the eccrine gland secretory coil -- because this patient's anhidrosis involves only the M3 muscarinic pathway (from the TRPV4 downstream signaling defect), he retains approximately 70% of his thermoregulatory capacity through the intact beta-2 adrenergic sweating pathway; the board should restrict field duty only in extreme heat conditions (above 38 degrees Celsius ambient temperature) rather than imposing complete field service restrictions.
• E) The risk of heat stroke in a soldier with anhidrosis is primarily from the accompanying loss of plasma volume that occurs during eccrine sweating -- without sweating, plasma volume is preserved during exercise, increasing central venous pressure and causing heat stroke through a paradoxical hypervolemic mechanism; the treatment is preemptive diuresis before field operations to reduce plasma volume to the level that would have been lost through sweat, restoring the physiological thermoregulatory set point.

8. [CASE 2 -- QUESTION 4] During workup, the soldier asks whether a topical muscarinic agonist cream applied to the skin before exercise might restore some sweating function and allow safe field duty. The physician must explain why topical muscarinic agonism alone cannot substitute for the intact sympathetic cholinergic pathway in providing thermoregulatory sweating. Which of the following most accurately constructs this pharmacological argument?

• A) Topical muscarinic agonist cream cannot restore thermoregulatory sweating because muscarinic agonists applied to the skin surface are immediately inactivated by the high concentration of acetylcholinesterase in the keratinocyte layer of the epidermis -- the drug never reaches the dermis or the eccrine secretory coil in pharmacologically active concentrations; only intradermal injection of a non-hydrolyzable muscarinic agonist such as bethanechol or methacholine could reach the deep eccrine glands, but this route is impractical for generalized application over the body surface.
• B) Topical muscarinic agonism is pharmacologically effective at activating eccrine sweat glands locally -- pilocarpine iontophoresis is used clinically for sweat testing in cystic fibrosis diagnosis; however, systemic transdermal absorption of any topical muscarinic agonist in concentrations sufficient to produce body-wide eccrine activation would also activate M3 receptors in bronchial smooth muscle (producing bronchoconstriction), in GI smooth muscle (producing cramping and diarrhea), in the heart's SA node M2 receptors (producing bradycardia), in the iris sphincter pupillae (producing miosis), and in salivary and lacrimal glands (producing hypersecretion) -- the systemic muscarinic toxidrome from the dose required for generalized body sweating would be clinically intolerable; furthermore, in this patient's case, if the deficit is post-receptor (downstream of M3 at the TRPV4 level), topical muscarinic agonism cannot overcome the transduction failure regardless of dose.
• C) Topical muscarinic agonist cream cannot restore thermoregulatory sweating because thermoregulatory sweating requires centrally coordinated, thermostatic feedback control from the hypothalamic preoptic area -- sweating occurs only in response to rising core temperature and is precisely regulated in proportion to the temperature error signal; no topical drug applied before exercise can replicate this dynamic thermostatic feedback system: a fixed topical dose produces maximal eccrine stimulation from the moment of application regardless of actual core temperature and cannot be modulated in response to changing thermal load; it cannot be turned down when core temperature is below the thermoregulatory threshold (potentially producing hypothermia from excessive heat loss at rest) or turned up further when core temperature rises during heavy exercise; additionally, in this patient with a TRPV4 loss-of-function variant, the post-receptor calcium signaling defect means that even effective M3 receptor activation would not produce sweat secretion; and systemic muscarinic agonism at concentrations needed for body-wide sweating would produce an intolerable cholinergic toxidrome.
• D) Topical muscarinic agonist creams cannot be used because muscarinic agonists are classified as Schedule II controlled substances under the Controlled Substances Act -- their topical application without a dermatologist's prescription is illegal; furthermore, muscarinic agonists do not penetrate intact skin without iontophoresis and passive topical application would produce zero pharmacological effect even at very high cream concentrations.
• E) Topical muscarinic agonism would work perfectly as a substitute for the intact sympathetic cholinergic pathway -- pilocarpine cream applied before exercise would produce sustained eccrine sweating equivalent to sympathetically driven thermoregulatory sweating; the only limitation is the cost and logistical burden of applying cream to the entire body surface before each field exercise; with a sufficiently efficient delivery system, the soldier could return to unrestricted field duty using pre-exercise pilocarpine application as a pharmacological substitute for his impaired sympathetic cholinergic pathway.